ADB-FUBINACA

ADB-FUBINACA (ADMB-FUBINACA^[2]) is a designer drug identified in synthetic cannabis blends in Japan in 2013.^[3][4] In 2018, it was the third-most common synthetic cannabinoid identified in drugs seized by the Drug Enforcement Administration.^[5]

Legal status

• BR: Class F2 (Prohibited psychotropics)^[1]
• CA: Schedule II
• DE: Anlage II (Authorized trade only, not prescriptible)
• UK: Class B
• US: Schedule I

CAS Number

• 1185282-00-1 ^Y

PubChem CID

• 70969086

ChemSpider

• 29763706

Quick facts Legal status, Identifiers ...

ADB-FUBINACA

Legal status
Legal status	BR: Class F2 (Prohibited psychotropics)[1] CA: Schedule II DE: Anlage II (Authorized trade only, not prescriptible) UK: Class B US: Schedule I
Identifiers
IUPAC name N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide
CAS Number	1185282-00-1 Y
PubChem CID	70969086
ChemSpider	29763706
UNII	05235E1S2O
KEGG	C22699 Y
CompTox Dashboard (EPA)	DTXSID701009981
Chemical and physical data
Formula	C21H23FN4O2
Molar mass	382.439 g·mol−1
3D model (JSmol)	Interactive image
SMILES O=C(NC(C(N)=O)C(C)(C)C)C1=NN(CC2=CC=C(F)C=C2)C3=C1C=CC=C3
InChI InChI=InChI=1S/C21H23FN4O2/c1-21(2,3)18(19(23)27)24-20(28)17-15-6-4-5-7-16(15)26(25-17)12-13-8-10-14(22)11-9-13/h4-11,18H,12H2,1-3H3,(H2,23,27)(H,24,28)/t18-/m1/s1 Key:ZSSGCSINPVBLQD-GOSISDBHSA-N

Close

The name is an acronym for N-(1-Amino-3,3-Dimethyl-1-oxoButan-2-yl)-1-(4-FlUoroBenzyl)-1H-INdAzole-3-CarboxAmide.

The (S)-enantiomer of ADB-FUBINACA is described in a 2009 Pfizer patent^[6] and has been reported to be a potent agonist of the CB₁ receptor and the CB₂ receptor with EC₅₀ values of 1.2 nM and 3.5 nM, respectively.^[6][7] ADB-FUBINACA features a carboxamide group at the 3-indazole position, like SDB-001 and STS-135. ADB-FUBINACA appears to be the product of rational drug design, since it differs from AB-FUBINACA only by the replacement of the isopropyl group with a tert-butyl group.

An analogue of ADB-FUBINACA, ADSB-FUB-187, containing a more functionalized carboxamide substituent was recently reported.